Sharpays Love: The company plans to carry out clinical trials of deoxyadrenaline ketoglutarate solution.

Sapphire announcement, recently, the company obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the solution of deoxyadrenaline ketone acid, and the company plans to conduct clinical trials after meeting the conditions. The drug is called deoxyadrenaline ketone acid solution, in the form of eye drops, mainly used for maintaining mydriasis during cataract surgery or artificial lens replacement surgery, preventing pupil constriction during surgery, and relieving postoperative eye pain. As of the date of this announcement, the project has accumulated approximately 5.5563 million RMB in research and development investment.